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OBJECTIVE—Patients with type 2 diabetes have an increased
risk of cardiovascular disease and show abnormalities in the
coagulation cascade. We investigated whether increased synthe-
sis of tissue factor (TF) by platelets could contribute to the
hypercoagulant state.
RESEARCH DESIGN AND METHODS—Platelets from type 2
diabetic patients and matched control subjects were adhered to
different surface-coated proteins, and TF premRNA splicing, TF
protein, and TF procoagulant activity were measured.
RESULTS—Different adhesive proteins induced different levels
of TF synthesis. A mimetic of active clopidogrel metabolite
(AR-C69931 MX) reduced TF synthesis by 56  10%, an aspirin-
like inhibitor (indomethacin) by 82  9%, and the combination by
96  2%, indicating that ADP release and thromboxane A2
production followed by activation of P2Y12 and thromboxane
receptors mediate surface-induced TF synthesis. Interference
with intracellular pathways revealed inhibition by agents that
raise cAMP and interfere with phosphatidylinositol 3-kinase/
protein kinase B. Insulin is known to raise cAMP in platelets and
inhibited collagen III–induced TF premRNA splicing and reduced
TF activity by 35  5 and 47  5% at 1 and 100 nmol/l. Inhibition
by insulin was reduced in type 2 diabetes platelets resulting in an
1.6-fold higher TF synthesis than in matched control subjects.
CONCLUSIONS—We characterized the extra- and intracellular
mechanisms that couple surface activation to TF synthesis in
adhering platelets. In healthy individuals, TF synthesis is inhib-
ited by insulin, but in patients with type 2 diabetes inhibition is
impaired. This leads to the novel ﬁnding that platelets from type
2 diabetic patients produce more TF than platelets from matched
control subjects. Diabetes 59:1487–1495, 2010
T
ype 2 diabetic patients have a two- to eightfold
higher risk of cardiovascular disease than
healthy individuals, and 80% will die of arterial
thrombosis–related disorders (1). Type 2 diabe-
tes induces a prothrombotic state caused by imbalance of
the hemostatic mechanism with evidence of hypercoagu-
lation, decreased ﬁbrinolysis, platelet hyperaggregability,
and endothelial dysfunction (2,3). Circulating markers for
activated coagulation, such as prothrombin fragment 1 
2 and thrombin-antithrombin complexes, are increased.
Also, the elevated levels of ﬁbrinogen; factors (F) VII, VIII,
and XI; and von Willebrand factor (VWF) might contribute
to the prothrombotic tendency (4). In particular, circulat-
ing tissue factor (TF) is increased (5), which, as the main
initiator of the coagulation cascade, might contribute to
hypercoagulability. Interestingly, improvement of glyce-
mic control lowers plasma TF (6).
The hyperaggregability of type 2 diabetes platelets might
be caused by loss of sensitivity to insulin. Under experi-
mental conditions, platelets of type 2 diabetic patients
show better adhesion to a prothrombotic surface, make
larger aggregates, have an increased procoagulant surface,
and have an elevated cytosolic Ca
2 concentration com-
pared with platelets from healthy control subjects (7).
Intensive insulin treatment partly normalizes platelet ag-
gregation (8). Indeed, insulin inhibits platelets from
healthy individuals but not from type 2 diabetic subjects
(9,10). Normally, platelet activators start signaling path-
ways that initiate aggregation and secretion while concur-
rently reducing the level of the intracellular inhibitor
cAMP through the G-protein subunit Gi2. Insulin inacti-
vates Gi2 through binding of insulin receptor substrate
(IRS)-1 to Gi2 (7,11). In type 2 diabetes platelets, this
property is lost presumably due to a defect in IRS-1. In
addition to signaling through Gi2, insulin releases Gi,
activating the phosphatidylinositol 3-kinase (PI3-K)/pro-
tein kinase B (PKB) pathway and increasing glucose
uptake through GLUT3 transporters (12,13).
A key step in the initiation of a hemostatic plug is TF
exposure. TF is an integral transmembrane protein (43
kDa) located on the plasma membrane (14). TF binds
activated FVII and the complex activates FVII, FIX, and
FX, generating thrombin and inducing clotting. TF is
constitutively expressed by vascular smooth muscle cells,
and vessel damage rapidly starts coagulation. Also, mono-
cytes and endothelial cells produce TF following a shift to
a prothrombotic phenotype induced by inﬂammatory fac-
tors such as lipopolysaccaride (LPS). Studies in mice with
a general and bone marrow–speciﬁc TF suppression show
that ﬁbrin propagation depends exclusively on blood-born
TF. The source of blood-born TF is sought in micropar-
ticles. They deliver TF in an encrypted state, which, upon
contact with the thrombus, changes to an active confor-
mation that initiates clotting (15). We showed recently that
TF production by LPS-stimulated monocytes is suppressed
by insulin via a mechanism similar but not identical to
insulin’s inhibition of platelet functions (16). Preliminary
data indicate that in type 2 diabetes monocytes have lost
sensitivity to insulin and produce more TF than their
normal counterparts.
Recent ﬁndings suggest a new source for TF expression
(17). The anucleate platelet has long been considered
incapable of synthesizing proteins, but the presence of a
splicing machinery, together with premRNAs for a number
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synthesis. In the present study, we investigated how
contact with adhesive proteins initiates platelet TF synthe-
sis and studied a possible interference by insulin in healthy
individuals and type 2 diabetic patients.
RESEARCH DESIGN AND METHODS
We obtained human recombinant insulin (solubilized according to the recom-
mendations of the manufacturer in 10 mmol/l acetic acid, 100 mmol/l NaCl,
and 0.01% BSA to a stock concentration of 100 mol/l); wortmannin; 1-(5-
chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine (ML-9); LPS (E.
coli 0111:B4); indomethacin; puromycin; collagen types I and III; ADP from
Sigma (St. Louis, MO); Akt inhibitor 1701-1 from Biovision (Mountain View,
CA); iloprost from Schering (Berlin, Germany); forskolin, BAPTA(AM), iono-
phore A23187, Tg003, and cantharidin from Calbiochem (La Jolla, CA);
LY294002 from Biomol (Plymouth Meeting, PA, USA); cycloheximide from MP
Biochemicals (Santa Ana, CA, USA); collagen reagent Horm from Nycomed
Pharma; a mixture of 95% type I and 5% type III collagen (Munich, Germany);
thrombin and ﬁbrinogen from Enzyme Research Laboratories (South Bend,
IN); and U-44619 from Cayman Chemicals (Ann Arbor, MI). Plasma-derived
VWF was puriﬁed from VWF/FVIII concentrate (Hemate P; Behring, Marburg,
Germany) (18). Factor X (FX) was puriﬁed from fresh-frozen plasma (19).
Recombinant FVIIa (rFVIIa) was from Novo Nordisk (Bagsværd, Denmark),
and recombinant TF (Innovin) was from Dade Behring (Liederbach, Ger-
many). Antibodies against the horseradish peroxidase–labeled anti-rabbit
antibody were from Cell Signaling Technology (Danvers, MA), anti–phospho-
Ser polyclonal antibody was from Upstate Biotechnology (Bucks, U.K.),
peroxidase-linked goat anti-mouse antibody was from DAKO (Glostrup,
Denmark), anti–splicing factor 2 (SF2)/–alternative splicing factor (ASF)
antibody was from Abcam (Cambridge, U.K.), anti-TF antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA) for immunoprecipitation and
Afﬁnity Biologicals (Ancaster, ON, Canada) for Western blotting, and anti-TF
pathway inhibitor (TFPI) antibody from American Diagnostica (Stamford,
U.K.) An inhibitory antibody against TF was a generous gift from Dr. M. Kjalke
(Hemostasis Biology, Novo Nordisk, Malov, Denmark). The ADP receptor
P2Y12 antagonist, N6-(2-methylthioethyl)-2-(3,3,3-triﬂuoropropylthio)-,-di-
chloromethylene ATP (AR-C69931MX), was a kind gift from Astra Zeneca
(Loughborough, U.K.). All other chemicals used were of analytical grade.
Isolated platelet suspensions were made monocyte free and adhered to
different surface-coated adhesive proteins. Splicing of TF premRNA and
synthesis of TF protein and TF procoagulant activity were measured. Phar-
macologic interference with extra- and intracellular signaling was investi-
gated, focusing speciﬁcally on the role of insulin in healthy individuals and
patients with type 2 diabetes.
The study had been approved by the medical ethical review board. Type 2
diabetic subjects were recruited from the outpatient clinics of the Utrecht
Medical University Hospital (Utrecht, the Netherlands). All patients were
anti-GAD negative and had plasma C-peptide levels 0.30 nmol/l. We recruited
insulin-using patients in order to circumvent the possibility that oral hypogly-
cemic agents interfere with the study; only metformin use was acceptable (it
was stopped the evening for the study). Six patients used four injections with
insulin per day, one used continuous subcutaneous insulin infusion. Their
further characteristics are given in Table 1. Patients and matched control
subjects gave their informed consent prior to participation in the study.
Platelet isolation. Freshly drawn venous blood from healthy volunteers and
type 2 diabetic patients was collected into 0.1 volume of 130 mmol/l Na3
citrate. Platelets were isolated as described (11).
Attempts to remove contaminating monocytes included 1) incubation of a
platelet suspension (2 	 10
8 platelets/ml) with either anti-CD14 antibody– or
anti-CD45 antibody–coupled beads (15 min, 22°C, 35 l anti-CD14 or anti-
CD45 beads per 40 	 10
8 platelets) and subsequent magnetic separation
(Miltenyi Biotec, Bergisch Gladbach, Germany) and 2) a double incubation of
a concentrated platelet suspension (15 	 10
8 platelets/ml) with a cocktail of
anti-CD14 antibody– and anti-CD45 antibody–coupled beads (15 min, 22°C, 35
l anti-CD14 and 35 l anti-CD45 beads per 40 	 10
8 platelets) and magnetic
separation. Contamination with monocytes was measured by RT-PCR of CD14
mRNA. To this end, total RNA was isolated using the kit from RNA-Bee (Tell
Tech, Friendswood, TX), and RT-PCR was performed using the forward
primer 5
-AAAGCACTTCCAGAGCCTGC-3
 and the reverse primer 5
-TC
GAGCGTCAGTTCCTTGAGG-3
 on a PTC-200 apparatus (MJ Research,
Waltham, MA).
TF expression. To investigate TF synthesis in platelets, an aliquot of
suspension (2 	 10
8 platelets) was incubated for static adhesion experiments
in six-well plates (Corning ultra-low attachment surface; Corning, Acton, MA)
or kept in suspension for the indicated times at 37°C. Wells were coated with
50 g/ml horm collagen, 50 g/ml collagen type I, 50 g/ml collagen type III,
1 unit/ml thrombin, 100 g/ml ﬁbrinogen, and 10 g/ml VWF for2ha t37°C.
For analysis of TF procoagulant activity, adhered platelets, collected in 250 l
HEPES/Tyrode buffer, or suspensions were lysed by freeze/thawing three
times and centrifuged (16200g, 2 min, 22°C). Pellet fractions were dissolved in
50 l HEPES/Tyrode buffer. Samples were incubated with 2 g/ml anti-TFPI
antibody (15 min, 22°C) and thereafter with 10 g/ml FX, 5 units/ml rFVIIa,
and 5 mmol/l CaCl2 (45 min, 37°C). FXa generation was measured in a
ﬂuorescence reader at 405 nm after addition of FXa substrate (Pentapharm,
Basel, Switzerland). Procoagulant activity was determined based on a stan-
dard curve derived from serial dilutions of recombinant TF.
For analysis of splicing of TF premRNA, 12 	 10
8 platelets were adhered to
a coated surface or kept in suspension, as indicated. Total RNA was isolated
(RNA-Bee; Tell Tech), and RNA levels adjusted for variations per sample (by
TABLE 1
Characteristics of the study population
Control group
Type 2 diabetic
patients P
n 88
Age (years) 52  35 8  3 0.2
BMI (kg/m
2) 25  0.9 28  2 0.2
Systolic blood pressure (mmHg) 140  7 131  3 0.2
Diastolic blood pressure (mmHg) 86  48 0  4 0.3
HbA1C (%) 5.5  0.09 7.3  0.5 0.002
Cholesterol (mmol/l) 6.1  0.4 4  0.3 0.001
Triglycerides (mmol/l) 1.7  0.3 1.9  0.4 0.6
HDL cholesterol 1.3  0.07 1.1  0.11 0.2
Creatinine (mol/l) 95  6.4 104  6 0.3
Management with insulin 8
Duration of diabetes (years) 16  2
C-peptide (nmol/l) 0.74  0.14 (0.34–1.64) 0.72  0.07 (0.39–1.05) 0.9
Smoking 3
Medication
Aspirin 0
Statin 5
ACE inhibitor or angiotensin
receptor blocker 8
Cardiovascular disease 2
Data are means  SE or means  SE (range).
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RT-PCR was performed on a PCR apparatus (PTC-200; MJ Research) using
primers that overlapped intron 4, with forward primer 5
-CTCGGACAGCCAA
CAATTCAG-3
 and reverse primer 5
-CGGGCTGTCTGTACTCTTCC-3
.
Alkaline phosphatase assay. The number of adhered platelets was inferred
from the content of alkaline phosphatase in collected samples, as published
(20). Alkaline phosphatase activity was related to platelet number using a
serial dilution of platelets in suspension.
Immunoprecipitation, SDS-PAGE, and Western blotting. To determine
levels of TF protein and the Ser phosphorylation of SF2, aliquots of 2 	 10
8
platelets were adhered to a coated surface in six-well plates or kept in
suspension (1 h, 37°C). Adhered platelets and suspensions were collected in
lysis buffer (1% NP40, 0.5% octylglucoside, 0.1% SDS, and 5 mmol/l EDTA
in PBS) supplemented with 10% protease inhibitor cocktail, 1 mmol/l NaVO3,
and 10 mol/l cantharidin. Proteins were precipitated with protein G-Sepha-
rose in combination with 1 g/ml anti-TF or anti-SF2 antibody overnight at
4°C. Precipitates were washed three times and dissolved in reducing Laemmli
sample buffer.
Proteins were analyzed by SDS-PAGE and Western blotting. After blocking
with Odyssey buffer (1 h, 22°C), membranes were incubated (16 h, 4°C) with
1 g/ml anti-TF, anti–phospho-Ser, or anti-SF2 antibody. Immunoblots were
visualized using the Odyssey infrared imaging system (LI-COR Biosciences,
Lincoln, NE) and Alexa-labeled antibodies according to the manufacturer’s
instructions. The intensity of the bands was quantiﬁed with ImageJ software.
Statistics. Data are expressed as means  SE, with n observations, and was
analyzed with Student t test for unpaired observations or Mann-Whitney U
test, as indicated. Differences were considered signiﬁcant at P  0.05.
RESULTS
Preparation of pure platelet suspensions. Since mono-
cytes have a much higher capacity to synthesize TF than
platelets, it was essential to prepare pure platelet suspen-
sions. Platelet preparations prepared by conventional
centrifugation/resuspension (7,11) without and with treat-
ment with anti-CD45 magnetic beads were positive for the
monocyte marker CD14 detected by RT-PCR (Fig. 1A, top
panel). Pure preparations were obtained by a double
incubation of concentrated suspensions with anti-CD14/
CD45 magnetic beads and monocyte removal by magnetic
sorting. After 35 cycli, RT-PCR of CD14 was negative in the
platelet preparation and positive in the eluate (Fig. 1A,
bottom panel). Upon stimulation with LPS, CD14-mRNA–
containing suspensions adhering to ﬁbrinogen synthesized
TF activity detected in the FXa assay, but CD14-mRNA–
negative preparations did not (Fig. 1B). To ensure purity of
platelet suspensions, a sample of adhered platelets with
LPS was included in all experiments, and series with
LPS-induced TF synthesis were discarded. Addition of
anti-TF antibody (0.5 mg/ml, 15 min, 22°C) completely
blocked TF activity in activated platelets conﬁrming spec-
iﬁcity of the FXa assay.
Activated platelets express TF by splicing of prem-
RNA. TF synthesis and TF premRNA splicing were studied
on ﬁbrinogen- and collagen-coated surfaces. Platelets ad-
hering to a ﬁbrinogen-coated surface (4 h, 37°C) synthe-
sized 0.24  0.04 ng TF/2 	 10
8 platelets (n  10). TF
synthesis in adhered platelets was inhibited by the trans-
lation blockers cycloheximide (58  2%, n  3) and
puromycin (76  6%, n  12) and the splicing blocker
Tg003 (51  7%, n  6) (Fig. 1C), conﬁrming earlier work
(17,21). To demonstrate splicing of TF premRNA, an
RT-PCR with primers overlapping intron 4 was performed
on platelets adhered to collagen type I (2 h, 37°C). The
result showed the expected band for spliced mRNA at 297
bp and for unspliced mRNA at 904 bp in the presence of
Tg003 (Fig. 1D). Regulation of TF premRNA splicing was
examined by measuring the Ser phosphorylation of SF2,
an effector of Cdc2-like kinase (Clk-1) (Fig. 1E). The low
levels of SF2-Ser phosphorylation in platelets in suspen-
sion were unchanged after stimulation with thrombin and
increased when platelets had adhered to ﬁbrinogen (4 h,
37°C). Tg003 reduced the phosphorylation, conﬁrming its
dependence on Clk-1. These results conﬁrm that adhering
platelets synthesize TF through splicing of premRNA.
Different splicing at different adhesive surfaces. The
question was addressed regarding which adhesive surface
induced the highest TF premRNA splicing. Puromycin was
used to separate translation-dependent TF activity from
background TF. TF synthesis on horm collagen, collagen I,
and thrombin was 0.34  0.10, 0.32  0.07, and 0.30 
0.05%, respectively. A lower TF activity was found on
ﬁbrinogen (0.24  0.04), collagen III (0.17  0.02%), and
VWF (0.09  0.03%) (n  4) (Fig. 2A). Since different
adhesive surfaces induced different extents of adhesion/
aggregation, bound platelets were quantiﬁed on the basis
of alkaline phosphatase content. The highest adhesion/
aggregation was found with collagen III, collagen I, and
horm collagen (125 	 10
6 platelets), whereas adhesion
to thrombin, ﬁbrinogen, and VWF was 30% lower (Fig.
2B). Expression per platelet and correction for back-
ground TF (deﬁned as 
TF activity), indicated that horm
collagen, thrombin, and collagen I induced the highest TF
synthesis followed by ﬁbrinogen, collagen III, and VWF
(Fig. 2C). Further experiments were based on collagen III,
because it induced the highest platelet adhesion and is
present in the vasculature. We examined whether adhered
platelets produce more TF than platelets in suspension.
Collagen III–adhered platelets (4 h, 37°C) produced 600-
fold more TF than platelets in suspension stimulated with
collagen III (0.17  0.09 and 0.0003  0.0001 ng TF/2.0 	
10
8 platelets, respectively, n  3), indicating that splicing
of TF premRNA is strongly facilitated by adherence to a
surface (Fig. 2D), in contrast with an earlier ﬁnding (17,21).
Inhibition of platelet TF synthesis. To examine the
mechanisms that couple surface activation to TF synthe-
sis, platelets were adhered to collagen III without and with
coincubation with AR-C69931 MX (which mimics blockade
of the P2Y12 receptor by the active metabolite of clopi-
dogrel), with indomethacin, an easily soluble COX-1 inhib-
itor which mimics the action of aspirin, or a combination.
The inhibitors did not change platelet adhesion during
prolonged contact with collagen III (Fig. 3A, insert).
AR-C69931 induced a 56  16% decrease in TF synthesis,
indicating that in its absence TF synthesis is enhanced by
ADP secretion and P2Y12 receptor–mediated signaling.
Indomethacin induced an even steeper reduction and
inhibited TF synthesis by 82  9%. The combination of the
two inhibitors reduced TF synthesis by 96  2% (n  4,
Fig. 3A). Thus, platelet TF synthesis strongly depends on
the extracellular feedback loops mediated by secretion of
granule ADP and release of thromboxane A2 (TxA2).
There was little effect of metabolic inhibitors on adhe-
sion (not shown). The adenylyl cyclase activator forsko-
lin and the stable prostacyclin mimetic iloprost raise
cAMP and inhibited TF synthesis on collagen III by 51  14
and 82  6%, respectively. BAPTA/AM, which lowers the
cytosolic Ca
2 concentration and quenches Ca
2 in-
creases in activated platelets, inhibited TF synthesis al-
most completely. Incubation with ionophore A23187 alone
did not change collagen III–induced TF synthesis, but
coincubation with 1 mmol/l Ca
2 increased TF synthesis
to 443  57%. Inhibitors of PI3-K (wortmannin, LY294002)
and PKB (Akt inhibitor 1701-1, ML-9) decreased TF syn-
thesis by 60%, indicating that in the absence of inhibi-
tors, the PI3-K/PKB pathway signals to TF premRNA
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FIG. 1. Platelet-speciﬁc splicing of TF premRNA and TF synthesis. A: Detection of leukocyte-speciﬁc CD14 RNA (422 bp) in monocytes (lane 1),
platelet suspensions prepared by conventional centrifugation/resuspension (lane 2), leukocyte-depleted (depl) platelet suspensions obtained by
incubation with either anti-CD14 or anti-CD45 magnetic beads (lane 3, top panel), or double incubation with anti-CD14 and anti-CD45 magnetic
beads (lane 3, bottom panel) and elution (lane 4, leukocyte-rich fraction). Controls RT and RNA show the presence of genomic DNA and the
speciﬁcity of the PCR (5,6). B: Lack of LPS-induced TF synthesis in CD14 mRNA-negative suspensions. CD14 mRNA-positive and CD14
mRNA-negative platelet (plt) suspensions without () and with (f)1g/ml LPS. Incubation with a blocking antibody against TF completely
inhibited TF activity in CD14 mRNA-negative suspensions. TF activity in ﬁbrinogen-adhered platelets without LPS stimulation was expressed as
100%. C: TF activity in ﬁbrinogen-adhered platelets (4 h, 37°C, ) is inhibited by the translation blockers cycloheximide and puromycin and the
splicing blocker Tg003 (in DMSO, f). D: Splicing by platelets adhering to collagen I (col I) (4 h, 37°C) demonstrating a shift from premRNA (904
bp) to mature mRNA (297 bp). E: Negative SF2 phosphorylation in resting and thrombin (thr)-stimulated platelet suspensions and positive SF2
phosphorylation in ﬁbrinogen-adhered platelets, which is inhibited by Tg003. Data are means  SE. n  3–12. A, D, and E: representative
examples for n  3.
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interfere with release of ADP/TxA2 and/or with signaling
from ADP/TxA2 receptors to the spliceosome, experiments
were repeated in the presence of excess of ADP (50
mol/l) and of the stable TxA2 analog U-46619 (2 mol/l).
Inhibition of TF synthesis by the metabolic inhibitors was
preserved, indicating that in addition to the known sup-
pression of ADP/TxA2 release, these blockers interfere
with the control of TF premRNA splicing (Fig. 3C). West-
ern blot analysis conﬁrmed that iloprost inhibited synthe-
sis of TF protein (Fig. 3D). Together, these data reveal
that surface-induced TF synthesis is inhibited by a rise
in cAMP strongly depends on cytosolic Ca
2 and is
induced by signaling through the PI3-K/PKB pathway.
Insulin inhibits collagen-induced TF synthesis in
platelets. Since surface-induced TF synthesis was sensi-
tive to agents that raise cAMP or inhibit the PI3-K/PKB
pathway, we addressed the question whether insulin inter-
feres with adhesion-induced TF synthesis. Platelets were
preincubated with 100 nmol/l insulin (5 min, 37°C) and
adhered to different adhesive surfaces. The degree of
inhibition differed between adhesive proteins and reached
94  6, 64  27, 76  27, 67  14, and 41  7% (n  5) for
horm collagen, thrombin, collagen I, ﬁbrinogen, and colla-
gen III, respectively. On VWF, no inhibition by insulin was
found (Fig. 4A). To elucidate whether insulin interferes
with splicing before or after release of ADP/TxA2, experi-
ments were repeated in the presence of excess of ADP and
TxA2 mimetic. Inhibition of collagen III–induced TF syn-
thesis was preserved, indicating that insulin inhibits TF
synthesis by interfering with the control of premRNA
splicing induced by ADP and TxA2 receptors (Fig. 4B).
Collagen III–adhered platelets were used to further evalu-
ate the inhibition by insulin. Adhered platelets showed a
dose-dependent inhibition between 1 and 100 nmol/l insu-
lin (Fig. 4C). Inhibition of premRNA splicing by insulin
was clearly detectable, showing decreased levels of ma-
ture mRNA compared with platelets in the absence of
insulin (Fig. 4D). In type 2 diabetic patients, collagen
III–induced TF activity inhibition by insulin was lost,
resulting in higher levels of collagen III–induced TF activ-
ity (96  12%, n  8) compared with matched control
subjects (59  12%, n  8; P  0.05 with Mann-Whitney U
test; Fig. 4E).
DISCUSSION
Novel ﬁndings in the present study are 1) the identiﬁcation
of the extra- and intracellular mechanisms that couple
surface activation to initiation of TF synthesis in platelets,
2) the inhibition of TF synthesis by insulin in normal
platelets, and 3) the loss of insulin inhibition in platelets
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of adhered platelets determined. A representative example of n  4 is shown. C: For different adhesive proteins surface-induced TF activity was
expressed per platelet, corrected for background TF and deﬁned as TF activity. D: Platelets adhering to collagen III (4 h, 37°C) produce 600-fold
more TF activity than the same platelet number in suspension stimulated with a same concentration of collagen III. A and C: TF activity in
ﬁbrinogen-adhered platelets was expressed as 100%. Data are means  SE. n  3–4.
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higher TF synthesis. The increased TF synthesis might be
a cause of the hypercoagulant state observed in type 2
diabetic patients and contribute to the increase in throm-
botic risk.
The presence of TF synthesis in platelets is controver-
sial. Some investigators attributed a positive outcome to
contamination with monocytes, which have a many-fold–
higher translation capacity (22–24). Therefore, we in-
cluded a purity check in every experiment to demonstrate
unequivocally that platelets synthesize TF. The CD14
mRNA–free platelet suspensions showed no TF premRNA
splicing upon stimulation with LPS, which is a potent
inducer of TF synthesis in monocytes (16). Apparently,
splicing of TF premRNA is not under control of the platelet
LPS receptor, which contrasts with other studies that
show LPS-induced splicing of interleukin (IL)-1 and
cyclooxygenase (COX)-2 premRNA in platelets (25).
Platelets adhering to surface-coated adhesive proteins
start splicing of TF premRNA and synthesis of TF protein
and induce the capacity to initiate coagulation, conﬁrming
earlier observations (17,21). The anucleate platelet has
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FIG. 3. Effect of inhibitors of signaling pathways on TF synthesis in platelets. A: Platelets were preincubated with a mimetic of active clopidogrel
metabolite (AR-C69931 MX, AR, 250 nmol/l), the aspirin-like inhibitor indomethacin (Indo, 100 mol/l) or the combination (15 min, 37°C).
AR-C69931 MX and indomethacin did not affect platelet adhesion (insert) but reduced surface-induced TF synthesis (4 h, 37°C). B: Platelets were
preincubated with the adenylyl cyclase activator forskolin (40 mol/l), the stable prostacyclin mimetic iloprost (1 g/ml), the Ca
2 quencher
BAPTA/AM (25 mol/l), ionophore A23187 (12 mol/l) in the absence and presence of CaCl2 (1 mmol/l), the PI3-K/PKB inhibitors wortmannin
(0.5 mol/l) and LY294002 (10 mol/l), the Akt inhibitor 1701-1 (2 mol/l), and ML-9 (100 mol/l) (15 min, 37°C). The inhibitors reduced the
surface-induced TF synthesis (4 h, 37°C). Addition of vehicle alone did not change surface-induced TF levels (as shown in Fig. 1C). C: Platelets
in the presence of excess of ADP and the TxA2 mimetic U-44619 were preincubated with iloprost, BAPTA/AM, wortmannin, LY294002, the Akt
inhibitor 1701-1, and ML-9 before platelets were adhered to collagen III (4 h, 37°C) and TF activity was determined. D: Platelets were adhered
to ﬁbrinogen (4 h, 37°C). The blot shows the 60-kDa band (in the presence of DTT) of monocyte (mono) TF, surface-induced platelet TF protein,
the inhibition by puromycin (puro), and by the cAMP-raising agent iloprost (ilo). A, insert and D: Representative example for n  3. A–C:T F
activity in collagen III–adhered platelets was expressed as 100%. Data are means  SE. n  3–4. *Denotes a signiﬁcant difference, P < 0.05. ns,
not signiﬁcant.
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Intron removal was thought to be conﬁned to the nucle-
ated megakaryocyte and platelet proteins to be the exclu-
sive result of transcription and translation in this
progenitor cell (26). Unexpectedly, the platelet cytoplasm
SF2/ASF, a regulator of constitutive and alternative splic-
ing (27) together with a number of premRNAs with mes-
sage for IL-1, B-cell lymphoma 3, plasminogen activator
inhibitor-1, COX-2, and TF (28–30). Platelets stimulated
with soluble agonists or adhering to ﬁbrinogen start for-
mation of mature RNAs and translation into functional
proteins. Splicing of TF premRNA results in formation of
TF protein and the capacity to start coagulation and is
under control of dual speciﬁcity Clk-1, which contains an
NH2-terminal region enriched in serine/arginine dipeptides
(SR) that interacts with SF2/ASF (31). Inhibition of splic-
ing by Tg003 and of protein synthesis by puromycin
conﬁrm that platelets are capable of transcription/transla-
tion-dependent TF synthesis (17). However, the inhibition
was incomplete, suggesting that platelets contain a small
store of encrypted TF that becomes active when the cells
adhere to an adhesive surface.
Splicing of TF premRNA was 600-fold more efﬁcient in
adhering platelets than in platelet suspensions, suggesting
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FIG. 4. Insulin inhibits synthesis of platelet TF. A: Platelets (plts) were
preincubated with 100 nmol/l insulin (5 min, 37°C) and adhered to
surface-coated horm collagen (horm), thrombin (thr), collagen I (col I),
ﬁbrinogen (fg), collagen III (col III), and VWF (4 h, 37°C), and TF activity
was measured. B: To the platelet suspension excess ADP and U-46619
were added and followed by preincubation with insulin (5 min, 37°C)
before platelets were adhered to collagen III (4 h, 37°C), and TF activity
was determined. C: Dose-dependent inhibition by insulin (ins) (5 min,
37°C) of TF synthesis by collagen III–adhered platelets. D: Splicing was
demonstrated by the presence of either premRNA or mature mRNA in
platelets that were untreated or preincubated with insulin and allowed to
adhere to collagen I (30 min, 37°C). A representative example of n  4i s
shown. E: Platelets from eight type 2 diabetic patients and eight matched
control subjects were preincubated with insulin (100 nmol/l, 5 min, 37°C)
and allowed to adhere to collagen III (4 h, 37°C), and TF activity was
measured. TF activity in adhered platelets without insulin from control
subjects and type 2 diabetic patients were not signiﬁcant different (0.17  0.05 vs. 0.28  0.13 ng TF/2.0  10
8 platelets, respectively). A–C
and E: F activity in ﬁbrinogen or collagen III–adhered platelets was set at 100%. Data are means  SE. n  3–8. mono, monocytes; ns, not
signiﬁcant. *Denotes a signiﬁcant difference, P < 0.05.
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cess. In adhered platelets, the P2Y12 receptor blocker
AR-C69931 MX inhibited TF synthesis by 56% and the
COX-1 blocker indomethacin by 82%, illustrating that
without inhibitors, TF synthesis is strongly enhanced by
ADP secretion and TxA2 formation and subsequent activa-
tion of the P2Y12 receptor (ADP) and TP/ receptors
(TxA2). The combination of the blockers reduced TF
synthesis almost by 100%. This observation might indicate
that in vivo signaling to TF premRNA splicing is inhibited
by the active clopidogrel metabolite as well as aspirin and
that the combination abolishes the major part of platelet
TF production. Apparently, there is little TF synthesis in
the absence of feedback activation by released ADP and
TxA2, indicating that surface receptors that trigger TF
premRNA splicing predominantly do so by inducing these
positive feedback pathways. Collagen I, horm collagen,
and thrombin had the strongest capacity to induce splicing
of TF premRNA. Fibrinogen and collagen III induced less
splicing, and VWF was the weakest activator. These dif-
ferences might reﬂect the contribution of ADP/TxA2 re-
lease in platelet activation by these agonists, which is
strong in horm collagen (32) and thrombin (33) activation,
weak in activation by surface-coated ﬁbrinogen (34), and
virtually absent in platelet activation by coated VWF (35).
Iloprost, BAPTA-AM, and inhibitors of PI3-K/PKB inhib-
ited surface-induced TF synthesis, indicating that negative
control through cAMP-dependent mechanisms and posi-
tive control through the PI3-K/PKB route determine the
rate of TF synthesis. In addition to a direct effect of these
inhibitors on the release of ADP/TxA2, inhibition of TF
activity also takes place after the released products start
further signaling through the P2Y12 and TxA2 receptors.
Protein kinase A (PKA)  and PKA are activated by an
increase in cAMP concentration induced by forskolin or
8-CPT-cAMP and phosphorylate SR proteins in vitro and
change splice site selection in vivo (36). PKB contributes
to phosphorylation of SR proteins, speciﬁcally SF2 (37),
which potentiate their binding to recently transcribed
mRNA and/or directly stimulate SR protein activities.
Interestingly, in monocytes, TF expression is under nega-
tive control by the PKB pathway (16,38). Here, PKB
inhibits nuclear factor-B activity (38), such in contrast to
anucleated platelets where PKB regulates the splicing
mechanism.
The induction of ADP/TxA2 release followed by signal-
ing from ADP/TxA2 receptors to the spliceosome is under
control of insulin. In normal platelets, insulin interferes
with the P2Y12 pathway by inducing the association of
IRS-1 with Gi2, thereby blocking Gi-mediated cAMP sup-
pression, which attenuates platelet functions. In addition,
insulin stimulates the PI3-K/PKB pathway, initiating glu-
cose uptake through upregulation of GLUT3 transporters
(7,13). Interference with cAMP suppression by insulin
impairs agonist-induced Ca
2 rises, aggregation, secretion,
and the generation of a procoagulant surface, and the
interference with TF synthesis presented here adds to the
list of platelet functions under negative control by insulin.
Platelet TF does not seem to play a role in acute injury,
since it takes long to express active TF. An animal model
of laser-induced vessel-wall injury (14) shows the ﬁrst
appearance of TF at 100 s after induction of vessel wall
damage, which is well before the ﬁrst sign of platelet TF
synthesis. Diabetes increases the risk of developing lower-
extremity arterial disease, which is one of the ﬁrst signs of
a generalized atherosclerotic disease (39). A key event in
the pathogenesis of type 2 diabetes is loss of atheroscle-
rotic plaque stability. When the ﬁbrous cap is disrupted, a
platelet plug forms, which continuously increases in size
until the lumen is completely obstructed. In the chronic
process of arterial occlusive disease, the slow but consis-
tent production of TF by platelets may well contribute to
the propagation and stabilization of a thrombus. Indeed,
previous studies have detected TF antigen and activity in
the atherosclerotic plaque (40). The elevated TF synthesis
in platelets form type 2 diabetic patients might result in a
more stable clot inducing occlusion of an artery at sites
where atherosclerotic lesions have developed.
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